Raymond James Maintains Bausch Health(BHC.US) With Hold Rating, Maintains Target Price $8
Raymond James Maintains Bausch Health(BHC.US) With Hold Rating, Cuts Target Price to $8
TD Cowen Maintains Bausch Health(BHC.US) With Hold Rating, Cuts Target Price to $7
Bausch Health Companies: Hold Rating Amid Lowered Earnings and Profitability Concerns
Bausch Health Is Maintained at Sector Perform by RBC Capital
Bausch Health Companies Analyst Ratings
RBC Capital Maintains Bausch Health(BHC.US) With Hold Rating, Raises Target Price to $10
BofA Securities Maintains Bausch Health(BHC.US) With Sell Rating, Maintains Target Price $5
Truist Financial Maintains Bausch Health(BHC.US) With Hold Rating
Cautious Outlook on Bausch Health: Sell Rating Amid Strategic Uncertainty and Tariff Concerns
Raymond James Maintains Bausch Health(BHC.US) With Hold Rating, Maintains Target Price $9
Raymond James Sticks to Its Hold Rating for Bausch Health Companies (BHC)
BofA Securities Maintains Bausch Health(BHC.US) With Sell Rating, Cuts Target Price to $5
Bausch Health Companies Inc. Is Maintained at Sector Perform by RBC Capital
Raymond James Maintains Bausch Health(BHC.US) With Hold Rating, Announces Target Price $9
Raymond James Maintains Bausch Health(BHC.US) With Hold Rating
TD Cowen Maintains Bausch Health(BHC.US) With Hold Rating, Maintains Target Price $12
RBC Capital Maintains Bausch Health(BHC.US) With Hold Rating, Cuts Target Price to $9
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Irhythm Technologies (IRTC) and Bausch Health Companies (BHC)
Truist Financial Maintains Bausch Health(BHC.US) With Hold Rating, Announces Target Price $7